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Abstract
Introduction: Mantle cell lymphoma is a rare non-Hodgkin’s lymphoma. It is a subtype of B-cell lymphoma with
frequent involvement of the bone marrow and the gastrointestinal tract. Isolated parotid gland involvement
seldom occurs. Here we report an unusual case of isolated infiltration of the parotid gland by mantle cell
lymphoma. The aim of our study is to correlate magnetic resonance imaging findings with the histological features
of the disease. To the best of our knowledge, no similar radiological findings of mantle cell lymphoma have been
published before.
Case presentation: A 72-year-old Caucasian woman presented with a painful left parotid enlargement. She was
diagnosed with mantle cell lymphoma involving the left submandibular gland seven years prior to presentation.
Her whole body CT scan showed the absence of pathologically enlarged lymph nodes. However, a magnetic
resonance imaging showed enlargement of her left parotid gland and an abnormal parenchyma with mixed-type
solid and cystic lesions. A biopsy of her left parotid gland and subsequent histological examination confirmed a
mantle cell lymphoma (common variant) relapse.
Conclusion: Although rare, the involvement of parotid gland with mantle cell lymphoma must be considered in
the differential diagnosis of parotid tumors.
Introduction
Mantle cell lymphoma (MCL) is a rare lymphoma that
accounts for approximately 5% to 7% of non-Hodgkin’s
lymphomas (NHL). It is usually characterized by an aggres-
sive clinical course with a median overall survival of two to
five years [1]. The involvement of extranodal sites is not
uncommon as patients usually have an advanced-stage dis-
ease at the time of diagnosis [2]. According to Argatoff
et al., the isolated extranodal location of the disease has
been referred in 25% of cases, whereas salivary glands are
rarely affected (only 3% of reported cases) [1]. Here we pre-
sent a case of MCL of the parotid gland. We have also cor-
related its appearance at MRI with its histological findings.
Case presentation
A 72-year-old Caucasian woman was referred to
the Department of Haematology, General Hospital
G. Papanikolaou, with a painful left parotid enlargement
but without any other physical findings. Seven years
prior to this presentation, she was diagnosed with MCL
in her left submandibular gland, which was treated with
surgical removal, radiotherapy, and a chemotherapy
regimen of cyclophosphamide, hydroxydaunorubicin
(Adriamycin), Oncovin (vincristine) and prednisone/pre-
dnisolone (CHOP). Her white blood cell (WBC) count
of 5100/μL was represented by a normal differential of
69% neutrophils, 25% lymphocytes (with normal mor-
phology), 5% monocytes and 1% eosinophils. Her hemo-
globin, hematocrit and platelet levels were normal at
12.7 g/dL, 38.4% and 219/μL, respectively. Her bone
marrow smears and biopsy were both normal without
evidence of any infiltration by lymphoma cells.
An ultrasound examination of our patient revealed
multiple cystic lesions in the parenchyma of her left par-
otid gland. Her MRI showed an enlargement of her left
parotid gland and the total replacement of her normal
parenchyma with mixed-type solid and cystic lesions
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(Figure 1). The solid components were mildly enhanced
after an intravenous administration of contrast medium
(Figures 2A and 2B). A whole body computed tomogra-
phy (CT) scan showed the absence of pathologically
enlarged lymph nodes. All the other organs of her chest
and abdomen were also found to be normal.
A biopsy of her left parotid gland and subsequent his-
tological examination showed the presence of MCL
(common variant). The MCL was composed of mono-
morphous small to medium-sized lymphoid cells which
most closely resembled centrocytes with a vaguely nodu-
lar growth pattern. The prominent neoplastic nodules
were adjacent to the cystic area (Figure 3A).
Immunostaining results for CD20, CD79a, CD43,
CD5, sIgM(l+) and cyclin D1 were positive (Figures 3B,
C and 3D) and negative for CD23 and CD3.
Our patient was treated with partial parotidectomy
and chemotherapy. Her post-operative course was
uncomplicated. Eighteen months after surgery she was
asymptomatic and disease-free.
Discussion
Mantle cell lymphoma is a relatively rare and aggressive
form of NHL. In the past, it has been referred to with
various names including intermediately differentiated
lymphocytic lymphoma, centrocytic lymphoma, and
mantle zone lymphoma [1]. MCL has a characteristic
morphological appearance consisting of small lymphoid
cells with slightly irregular nuclear cells. Its histological
growth patterns are of a nodular or diffuse type, or a
combination of these two types [2,3]. In nodular MCL,
some or many of the nodules may consist of follicles
with reactive germinal centers surrounded by broad
mantles of small lymphoid cells or the so-called mantle
zone pattern [2]. Later in the course of the disease the
mantle zonal or nodular pattern progresses to a diffuse
pattern [4].
The immunohistological features of MCL reveal a
characteristic phenotype. The cells express relatively
intense surface immunoglobulin M (IgM) and/or immu-
noglobulin D (IgD) and are usually positive for CD5,
Figure 1 Axial T2-weighted image reveals an enlargement of the left parotid gland and a total replacement of the normal
parenchyma with mixed-type solid and cystic lesions.
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Figure 2 (A) Coronal T1-weighted image shows the inhomogenic appearance of the left parotid gland. (B) Coronal T1-weighted image
after gadolinium contrast injection shows mild enhancement of the solid components, while the cystic areas remain hypodense.
Figure 3 (A) Microscopic appearance shows prominent vaguely neoplastic nodules (arrows) which are adjacent to the cystic area (red
area) (hematoxylin and eosin staining, ×25 magnification). (B) Immunohistochemical stains for CD20, (C) CD5, and (D) cyclin D1 are positive
(×100 magnification).
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FMC7 and CD43, but negative for CD10 and BCL6.
CD23 is negative or weakly positive. Almost all cases of
MCL are moderately to strongly positive for cyclin D1.
Cyclin D1 expression can be detected in a subset of
cases of chronic lymphocytic leukemia (CLL) and/or
small cell lymphoma (SLL) and hairy cell leukemia.
Usually, cyclin D1 is weakly positive in these neoplasms.
Cyclin D1 can also be expressed strongly in approxi-
mately one-quarter of plasma cell myeloma cases.
Conventional cytogenetic analysis demonstrates a
translocation between the immunoglobulin heavy chain
and cyclin D1 (CCND1, BCL1 and PRAD1) genes,
t(11;14)(q13;q32) in 70% to 75% of cases. However,
almost all cases demonstrate the rearrangement of these
genes using fluorescence in situ hybridization (FISH)
probes [5]. This translocation can rarely occur in other
types of B-cell NHL, in lymphocytic leukemia, and in
multiple myeloma [2]. Therefore, cytogenetic findings
need to be correlated with its pathological and immuno-
logical features to confirm a diagnosis of MCL.
Clinically, MCL occurs in middle-aged to older indivi-
duals with a median age of about 60 years, and predo-
minantly in men [2]. Most patients present with a stage
III or IV disease. According to Argatoff et al., in a clini-
copathological study of 80 cases, extranodal involvement
at presentation occurred in 76% of cases and the most
common sites were the bone marrow (63%), peripheral
blood (34%), gastrointestinal tract (10%) and Waldeyer’s
ring (10%). In 25% of cases the extranodal location was
the disease’s primary presentation, while the most com-
mon sites were the Waldeyer’s ring (6%), intestine (5%),
orbit (3%) and salivary gland (3%) [1].
MRI is the method of choice when treating patients
with palpable parotid gland masses to assess the exact
extent of the tumors, the invasion of neighboring struc-
tures, perineural spread, and lymph nodes staging [6].
Most parotid tumors, whether benign or malignant,
rarely replace the parenchyma of the gland totally.
Moreover, diffuse infiltration is often seen in lympho-
mas. The lymphomas have a homogenous signal pattern
with low intensity on T1-weighted and high intensity on
T2-weighted sequences. Although this MRI pattern is
highly suggestive of the lymphoma, there is no absolute
correlation between the imaging morphology and the
histology of the lesion [7].
In this case, our patient’s MRI showed an enlargement
of her left parotid gland and a total replacement of her
normal parenchyma with mixed-type solid and cystic
lesions. The solid components were mildly enhanced
using contrast medium. This appearance reflected the his-
tological pattern of the lesion as MCL was composed of
neoplastic nodules which were adjacent to the cystic area.
To the best of our knowledge, there are no other pub-
lished radiological findings on MCL of the parotid gland.
The differential diagnosis includes benign and malignant
parotid tumors, especially Warthin tumors and adenoid
cystic carcinomas, which may also have a solid cystic
appearance. These tumors rarely occupy the total gland
parenchyma. In particular, Warthin tumors are bilateral in
up to 10% of cases reported. They present as well-circum-
scribed, partly cystic and partly solid lesions on MRI and
are often located in the tail of the parotid gland. Adenoid
cystic carcinoma usually presents as an infiltrating mass
with a high propensity for perineural invasion. On MRI
adenoid cystic carcinoma has an irregular contour, poorly
defined margins, and a strong enhancement after the
administration of contrast medium [6].
Special caution is required in the follow-up examina-
tion of patients with primary Sjögren’s syndrome, as the
risk of developing a lymphoma is increased. In this case
the typical inhomogeneous nodular MRI picture seen in
Sjögren’s syndrome will change into a homogeneous
pattern that can involve the parenchyma partially or
even entirely [7].
Conclusion
Isolated parotid gland involvement by MCL is very rare
but should be considered nonetheless in the differential
diagnosis when replacement of a patient’s normal paro-
tid parenchyma with mixed-type solid and cystic lesions
is involved.
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